Evidence map›Paper›PMID 42816720›Full record

ArticlePharmaceutical research2026

Platinum(IV) Complexes Suppress Tumor Growth in MDA-MB-231 Cells and a DMBA- Induced Mammary Carcinoma Model.

Amjad Slika, Saba Al Alam, Joelle Bou Chacra, Christina Haydar, Chris Abou Jaoude, Joe Bou Gharios, Joya Maria Mrad, Stephanie Mehanna, Maria George Elias, Krishant M Deo and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amjad SlikaSchool of Arts and Sciences, Department of Biological Sciences, Lebanese American University, Byblos, Mount Lebanon, Lebanon.
Saba Al AlamSchool of Arts and Sciences, Department of Biological Sciences, Lebanese American University, Byblos, Mount Lebanon, Lebanon.
Joelle Bou ChacraSchool of Arts and Sciences, Department of Biological Sciences, Lebanese American University, Byblos, Mount Lebanon, Lebanon.
Christina HaydarSchool of Arts and Sciences, Department of Biological Sciences, Lebanese American University, Byblos, Mount Lebanon, Lebanon.
Chris Abou JaoudeSchool of Arts and Sciences, Department of Biological Sciences, Lebanese American University, Byblos, Mount Lebanon, Lebanon.
Joe Bou Gharios
Joya Maria MradSchool of Arts and Sciences, Department of Biological Sciences, Lebanese American University, Byblos, Mount Lebanon, Lebanon.
Stephanie MehannaSchool of Arts and Sciences, Department of Biological Sciences, Lebanese American University, Byblos, Mount Lebanon, Lebanon.
Maria George EliasSchool of Science, Western Sydney University, Locked Bag 1797 Penrith South, Penrith South, NSW, 2751, Australia.
Krishant M DeoSchool of Science, Western Sydney University, Locked Bag 1797 Penrith South, Penrith South, NSW, 2751, Australia.
Robin I TalebSchool of Arts and Sciences, Department of Biological Sciences, Lebanese American University, Byblos, Mount Lebanon, Lebanon.
Janice R Aldrich-WrightSchool of Science, Western Sydney University, Locked Bag 1797 Penrith South, Penrith South, NSW, 2751, Australia.
Costantine F DaherSchool of Arts and Sciences, Department of Biological Sciences, Lebanese American University, Byblos, Mount Lebanon, Lebanon. cdaher@lau.edu.lb.ORCID http://orcid.org/0000-0002-8275-7263

Funding

Lebanese American University PIRF I0054
6 · The paper itself

Abstract

purposeThe anticancer activity of two platinum(IV) complexes, P-PENT and P-HEX, was evaluated against MDA-MB-231 triple negative breast cancer cells and DMBA-induced mammary carcinoma in rats.

methodMDA-MB-231 and MCF-7 cell viability was evaluated using WST-1 kit. Biological characterization was carried out on MDA-MB-231 cells. Subcellular localization of platinum complexes were assessed with a subcellular fractionation kit and ICP-MS. Apoptosis and ROS production were assessed by flow cytometry and cell-permeant fluorogenic probe 2',7'-dichlorofluorescein diacetate, respectively. Dose escalation study was conducted on rats. Chemotherapeutic activity of P-PENT and P-HEX was evaluated for 4 weeks using a DMBA-induced breast carcinogenesis rat model.

resultsP-PENT and P-HEX were ~ tenfold more cytotoxic than cisplatin against MDA-MB-231 cells and 8.6- and 5.8-fold more cytotoxic against MCF-7 cells, respectively, while showing ~ tenfold lower toxicity to rat bone marrow MSCs (Selectivity Index: 8.9, 9.5 vs. 0.3). Both complexes showed peak intracellular accumulation at 24 h with higher and faster uptake than cisplatin. P-PENT is mostly localized in the nuclear/cytoskeletal fraction (42%) and P-HEX in the cytoplasmic fraction (62%). A significant increase in ROS production and apoptotic type of cell death were observed post treatment with P-PENT and P-HEX. Maximum tolerated doses were 45 and 40 mg/kg for P-PENT and P-HEX, respectively; both significantly inhibited mammary tumor growth (15 mg/kg; IP; weekly) without detectable toxicity.

conclusionP-PENT and P-HEX exhibited potent antitumor activity against breast cancer both in vitro and in vivo and may be considered as promising candidates for further preclinical investigation.

Indexed as

apoptosisbreast cancerchemotherapyMDA-MB-231cellsplatinum(iv)

Identifiers

PMID42816720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.